ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

BCRX vs VCEL // GROSS PROFIT MARGIN

BioCryst Pharmaceuticals Inc. (NASDAQ) VS. Vericel Corporation (NASDAQ) • 15-METRIC TALLY: BCRX 5 — VCEL 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BCRX VS. VCEL) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC BCRX VCEL SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE — 74.40% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 85.00% 3.40% +81.60 BCRX /roic <GO>
EV/EBITDA & P/E Valuation 6.1x 61.4x -55.30 BCRX /valuation <GO>
Free Cash Flow Yield 15.96% 1.13% +14.83 BCRX /fcf-yield <GO>
Operating Margin — 4.00% — TIE /operating-margins <GO>
Net Profit Margin — 6.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 16.50% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 9.94 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 6/9 8/9 -2.00 VCEL /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 54.8 46.2 +8.66 BCRX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 7.7x 111.7x -104.00 BCRX /forward-pe <GO>
Enterprise Scale & Market Cap $2.18B $2.20B -$20.1M VCEL /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR BCRX REV VCEL REV BCRX GROSS % VCEL GROSS % BCRX FCF VCEL FCF
FY 2025 $0 $276.3M — 74.4% $347.4M $24.7M
FY 2024 $0 $237.2M — 72.6% -$52.0M -$5.8M
FY 2023 $0 $197.5M — — -$95.1M $35.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BCRX // BETA —
VCEL // BETA —